The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Effects of Common Cancer Mutations on Stability and DNA Binding of Full-length p53 Compared with Isolated Core Domains
Abstract
Common cancer mutations of p53 tend either to lower the stability or distort the core domain of the protein or weaken its DNA binding affinity. We have previously analyzed in vitro the effects of mutations on the core domain of p53. Here, we extend those measurements to full-length p53, using either the wild-type protein or a biologically active superstable construct that is more amenable to accurate biophysical measurements to assess the possibilities of rescuing different types of mutations by anticancer drugs. The tetrameric full-length proteins had similar apparent melting temperatures to those of the individual domains, and the structural mutations lowered the melting temperature by similar amounts. The thermodynamic stability of tetrameric p53 is thus dictated by its core domain. We determined that the common contact mutation R273H weakened binding to the gadd45 recognition sequence by approximately 700-1000 times. Many mutants that have lowered melting temperatures should be good drug targets, although the common R273H mutant binds response elements too weakly for simple rescue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both Taz2 and a 24-residue gadd45 response element DNA bind p53 with Kd in the low nanomolar range (11, 30, 31)”
From Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain (2008) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Feng, L., Lin, T., Uranishi, H., Gu, W., & Xu, Y. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5389-5395.2005 · Cited by 236
Core domain interactions in full-length p53 in solution
Veprintsev, D. B., Freund, S. M. V., Andreeva, A., Rutledge, S. E., Tidow, H., Cañadillas, J. M. P., Blair, C. M., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511130103 · Cited by 95
Self-citationMenendez, D., Inga, A., & Resnick, M. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2297-2308.2006 · Cited by 81
Research works printed but not linked: 40
- Beroud, 1998, Nucleic Acids Res., 26, 200, 10.1093/nar/26.1.200 · DOI
- Hainaut, 2000, Adv. Cancer Res., 77, 81, 10.1016/S0065-230X(08)60785-X · DOI · Paper page
- Bullock, 1997, Proc. Natl. Acad. Sci. U. S. A., 94, 14338, 10.1073/pnas.94.26.14338 · DOI · Paper page
- Bullock, 2000, Oncogene, 19, 1245, 10.1038/sj.onc.1203434 · DOI · Paper page
- Bullock, 2001, Nat. Rev. Cancer, 1, 68, 10.1038/35094077 · DOI · Paper page
- Joerger, 2005, J. Biol. Chem., 280, 16030, 10.1074/jbc.M500179200 · DOI · Paper page
- Fields, 1990, Science, 249, 1046, 10.1126/science.2144363 · DOI · Paper page
- Müller-Tiemann, 1998, Proc. Natl. Acad. Sci. U. S. A., 95, 6079, 10.1073/pnas.95.11.6079 · DOI
- Walker, 1996, Proc. Natl. Acad. Sci. U. S. A., 93, 15335, 10.1073/pnas.93.26.15335 · DOI · Paper page
- Jeffrey, 1995, Science, 267, 1498, 10.1126/science.7878469 · DOI · Paper page
- Ahn, 2001, Nat. Struct. Biol., 8, 730, 10.1038/nsb0901-730 · DOI
- Balagurumoorthy, 1995, Proc. Natl. Acad. Sci. U. S. A., 92, 8591, 10.1073/pnas.92.19.8591 · DOI
- Weinberg, 2004, J. Mol. Biol., 341, 1145, 10.1016/j.jmb.2004.06.071 · DOI · Paper page
- Hupp, 1992, Cell, 71, 875, 10.1016/0092-8674(92)90562-Q · DOI · Paper page
- Espinosa, 2001, Mol. Cell, 8, 57, 10.1016/S1097-2765(01)00283-0 · DOI · Paper page
- Anderson, 1997, Mol. Cell Biol., 17, 6255, 10.1128/MCB.17.11.6255 · DOI
- Bayle, 1995, Proc. Natl. Acad. Sci. U. S. A., 92, 5729, 10.1073/pnas.92.12.5729 · DOI
- Prives, 2001, Cell, 107, 815, 10.1016/S0092-8674(01)00619-5 · DOI · Paper page
- McKinney, 2004, Mol. Cell, 16, 413, 10.1016/j.molcel.2004.09.032 · DOI · Paper page
- Weinberg, 2004, J. Mol. Biol., 342, 801, 10.1016/j.jmb.2004.07.042 · DOI · Paper page
- Bakalkin, 1995, Nucleic Acids Res., 23, 362, 10.1093/nar/23.3.362 · DOI · Paper page
- Friedler, 2005, Structure, 13, 629, 10.1016/j.str.2005.01.020 · DOI · Paper page
- Friedler, 2002, Proc. Natl. Acad. Sci. U. S. A., 99, 937, 10.1073/pnas.241629998 · DOI · Paper page
- Wiman, 2006, Cell Death Differ., 13, 921, 10.1038/sj.cdd.4401921 · DOI
- Bykov, 2003, Eur. J. Cancer, 39, 1828, 10.1016/S0959-8049(03)00454-4 · DOI
- Nikolova, 1998, Proc. Natl. Acad. Sci. U. S. A., 95, 14675, 10.1073/pnas.95.25.14675 · DOI · Paper page
- Joerger, 2004, J. Biol. Chem., 279, 1291, 10.1074/jbc.M309732200 · DOI · Paper page
- Weinberg, 2005, J. Mol. Biol., 348, 589, 10.1016/j.jmb.2005.03.014 · DOI · Paper page
- Chen, 1993, Oncogene, 8, 2159
- Chumakov, 1993, Oncogene, 8, 3005
- Pietenpol, 1994, Proc. Natl. Acad. Sci. U. S. A., 91, 1998, 10.1073/pnas.91.6.1998 · DOI · Paper page
- Chan, 2004, Mol. Cell Biol., 24, 3536, 10.1128/MCB.24.8.3536-3551.2004 · DOI · Paper page
- Rowan, 1996, EMBO J., 15, 827, 10.1002/j.1460-2075.1996.tb00418.x · DOI · Paper page
- Ryan, 1998, Mol. Cell Biol., 18, 3692, 10.1128/MCB.18.7.3692 · DOI · Paper page
- Campomenosi, 2001, Oncogene, 20, 3573, 10.1038/sj.onc.1204468 · DOI
- Resnick, 2003, Proc. Natl. Acad. Sci. U. S. A., 100, 9934, 10.1073/pnas.1633803100 · DOI · Paper page
- Nikolova, 2000, EMBO J., 19, 370, 10.1093/emboj/19.3.370 · DOI · Paper page
- Kraulis, 1991, J. Appl. Crystallogr., 24, 946, 10.1107/S0021889891004399 · DOI · Paper page
- Merritt, 1997, Methods Enzymol., 277, 505, 10.1016/S0076-6879(97)77028-9 · DOI · Paper page
- Gill, 1989, Anal. Biochem., 182, 319, 10.1016/0003-2697(89)90602-7 · DOI · Paper page
Cited by
mCSM: Predicting the effects of mutations in proteins using graph-based signatures
Pires, D. E. V., Ascher, D. B., & Blundell, T. L. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt691 · Cited by 1,066
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Structural Biology of the Tumor Suppressor p53
Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 693
Self-citationThe p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 661
Self-citationGain of function of mutant p53 by coaggregation with multiple tumor suppressors
Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.546 · Cited by 543
SDM: a server for predicting effects of mutations on protein stability
Pandurangan, A. P., Ochoa-Montaño, B., Ascher, D. B., & Blundell, T. L. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx439 · Cited by 497
Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain
Wells, M., Tidow, H., Rutherford, T. J., Markwick, P., Jensen, M. R., Mylonas, E., Svergun, D. I., Blackledge, M., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801353105 · Cited by 434
Self-citationStructure–function–rescue: the diverse nature of common p53 cancer mutants
Joerger, A. C., & Fersht, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210291 · Cited by 434
Self-citationTargeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 387
Self-citationThe Tumor Suppressor p53: From Structures to Drug Discovery
Joerger, A. C., & Fersht, A. R. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000919 · Cited by 357
Self-citationStructural basis for understanding oncogenic p53 mutations and designing rescue drugs
Joerger, A. C., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607286103 · Cited by 353
Self-citationReactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova, G., & Wiman, K. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210295 · Cited by 186
A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
Guiley, K. Z., & Shokat, K. M. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0381 · Cited by 102
Degtjarik, O., Golovenko, D., Diskin-Posner, Y., Abrahmsén, L., Rozenberg, H., & Shakked, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-27142-6 · Cited by 78
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Ang, H. C., Joerger, A. C., Mayer, S., & Fersht, A. R.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-08
- Volume
- 281
- Issue
- 31
- Pages
- 21934-21941
- ISSN
- 0021-9258
- Cited by
- 134
- References
- 8
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5186 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.